The DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.
Comparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta-analysis
Open accessAbstract
Importance: The clinical benefits of novel treatments for moderate to severe psoriasis are well established, but wide variations exist in patient response across different therapies. In the absence of head-to-head randomized trials, meta-analyses synthesizing data from multiple studies are needed to assess comparative efficacy among psoriasis treatments. Objective: To estimate the relative short-term and long-term efficacy of biologics and oral agents for the treatment of moderate to severe psoriasis. Data Sources: A systematic literature review was conducted on December 4, 2017, and updated on September 17, 2018. The Embase, MEDLINE, and Cochrane Central Register databases were included. Study Selection: Phase 2, 3, or 4 randomized clinical trials of treatments licensed by the US Food and Drug Administration and the European Medicines Agency for adults with moderate to severe psoriasis with data on Psoriasis Area and Severity Index assessment of 75%, 90%, and 100% reductions (PASI 75, 90, and 100) at 10 to 16 weeks (short-term efficacy) or 44 to 60 weeks (long-term efficacy) from baseline. Data Extraction and Synthesis: Data were extracted based on the Preferred Reporting Items for Systematic Review and Meta-analysis guidelines. A bayesian network meta-analysis was conducted to estimate short-term PASI response rates; to account for variation across trials, an ordinal model that adjusted for reference arm response was implemented. The long-term PASI rates were estimated via a traditional meta-analysis. Main Outcomes and Measures: PASI 75, 90, and 100 response rates at 10 to 16 weeks and 44 to 60 weeks from baseline. Results: Sixty trials meeting all inclusion criteria were included. At weeks 10 to 16, the highest PASI 90 rates were seen with risankizumab-rzaa (71.6%; 95% credible interval [CrI], 67.5%-75.4%), brodalumab (70.8%; 95% CrI, 66.8%-74.6%), ixekizumab (70.6%; 95% CrI, 66.8%-74.6%), and guselkumab (67.3%; 62.5%-71.9%). At weeks 44 to 60, the treatments with the highest PASI 90 rates were risankizumab-rzaa (79.4%, 95% CI, 75.5%-82.9%), guselkumab (76.5%; 95% CI, 72.1%-80.5%), brodalumab (74.0%; 95% CI, 69.3%-78.1%), and ixekizumab (73.9%; 95% CI, 69.9%-77.5%). Findings were consistent for short-term and long-term PASI 75 and 100 responses. Conclusions and Relevance: This study provides an assessment of the comparative efficacy among treatments for moderate to severe plaque psoriasis. The meta-analysis suggests that brodalumab, guselkumab, ixekizumab, and risankizumab-rzaa were associated with the highest PASI response rates in both short-term and long-term therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Hutton, B., Salanti, G., Caldwell, D. M., Chaimani, A., Schmid, C. H., Cameron, C., Ioannidis, J. P. A., Straus, S., Thorlund, K., Jansen, J. P., et al. (2015) · Annals of Internal Medicine · doi:10.7326/m14-2385 · Cited by 8,269
Secukinumab in plaque psoriasis—results of two phase 3 trials
Langley, R. G., Elewski, B. E., Lebwohl, M., Reich, K., Griffiths, C. E. M., Papp, K., Puig, L., Nakagawa, H., Spelman, L., Sigurgeirsson, B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314258 · Cited by 1,997
Leonardi, C. L., Kimball, A. B., Papp, K. A., Yeilding, N., Guzzo, C., Wang, Y., Li, S., Dooley, L. T., & Gordon, K. B. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60725-4 · Cited by 1,874
Papp, K. A., Langley, R. G., Lebwohl, M., Krueger, G. G., Szapary, P., Yeilding, N., Guzzo, C., Hsu, M.-C., Wang, Y., Li, S., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60726-6 · Cited by 1,361
Dias, S., Sutton, A. J., Ades, A. E., & Welton, N. J. (2013) · Medical Decision Making · doi:10.1177/0272989x12458724 · Cited by 1,207
Etanercept as Monotherapy in Patients with Psoriasis
Leonardi, C. L., Powers, J. L., Matheson, R. T., Goffe, B. S., Zitnik, R., Wang, A., & Gottlieb, A. B. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030409 · Cited by 1,175
Reich, K., Nestle, F. O., Papp, K., Ortonne, J.-P., Evans, R., Guzzo, C., Li, S., Dooley, L. T., & Griffiths, C. E. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67566-6 · Cited by 1,045
Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis
Papp, K. A., Leonardi, C., Menter, A., Ortonne, J.-P., Krueger, J. G., Kricorian, G., Aras, G., Li, J., Russell, C. B., Thompson, E. H. Z., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109017 · Cited by 941
Self-citationBlauvelt, A., Papp, K. A., Griffiths, C. E. M., Randazzo, B., Wasfi, Y., Shen, Y.-K., Li, S., & Kimball, A. B. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.11.041 · Cited by 897
Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial
Chaudhari, U., Romano, P., Mulcahy, L., Dooley, L., Baker, D., & Gottlieb, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04954-0 · Cited by 890
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial
Menter, A., Tyring, S. K., Gordon, K., Kimball, A. B., Leonardi, C. L., Langley, R. G., Strober, B. E., Kaul, M., Gu, Y., Okun, M., et al. (2008) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2007.09.010 · Cited by 889
Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis
Griffiths, C. E. M., Strober, B. E., van de Kerkhof, P., Ho, V., Fidelus-Gort, R., Yeilding, N., Guzzo, C., Xia, Y., Zhou, B., Li, S., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0810652 · Cited by 859
Griffiths, C. E. M., Reich, K., Lebwohl, M., van de Kerkhof, P., Paul, C., Menter, A., Cameron, G. S., Erickson, J., Zhang, L., Secrest, R. J., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60125-8 · Cited by 834
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
Lebwohl, M., Strober, B., Menter, A., Gordon, K., Weglowska, J., Puig, L., Papp, K., Spelman, L., Toth, D., Kerdel, F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503824 · Cited by 828
Self-citationReich, K., Armstrong, A. W., Foley, P., Song, M., Wasfi, Y., Randazzo, B., Li, S., Shen, Y.-K., & Gordon, K. B. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.11.042 · Cited by 761
Self-citationSaurat, J. ‐., Stingl, G., Dubertret, L., Papp, K. A., Langley, R. G. B., Ortonne, J. ‐., Unnebrink, K., Kaul, M., Camez, A., & for the CHAMPION Study Investigators (2007) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2007.08315.x · Cited by 728
Papp, K. A., Tyring, S., Lahfa, M., Prinz, J., Griffiths, C. E. M., Nakanishi, A. M., Zitnik, R., van de Kerkhof, P. C. M., & the Etanercept Psoriasis Study Group (2005) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2005.06688.x · Cited by 693
Meta‐Analysis in Medical Research: The Handbook for the Understanding and Practice of Meta‐Analysis
(2005) · Wiley eBooks · doi:10.1002/9780470994894 · Cited by 687
Papp, K., Reich, K., Leonardi, C. L., Kircik, L., Chimenti, S., Langley, R. G. B., Hu, C., Stevens, R. M., Day, R. M., Gordon, K. B., et al. (2015) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2015.03.049 · Cited by 678
Gordon, K. B., Strober, B., Lebwohl, M., Augustin, M., Blauvelt, A., Poulin, Y., Papp, K. A., Sofen, H., Puig, L., Foley, P., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31713-6 · Cited by 678
Self-citationMeta-Analysis in Medical Research
Sathian, B., Sreedharan, J., Ahmad, M. Z., Joy, T., Baboo, N., Dixit, S., & Devkota, S. (2009) · Cited by 652
Diagnosis and management of psoriasis.
Kim, W. B., Jerome, D., & Yeung, J. (2017) · Europe PMC (PubMed Central) · Cited by 634
The immunologic basis for the treatment of psoriasis with new biologic agents
Krueger, J. G. (2002) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2002.120568 · Cited by 600
Gottlieb, A. B., Evans, R., Li, S., Dooley, L. T., Guzzo, C. A., Baker, D., Bala, M., Marano, C. W., & Menter, A. (2004) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2004.02.021 · Cited by 581
Reich, K., Papp, K. A., Blauvelt, A., Tyring, S. K., Sinclair, R., Thaçi, D., Nograles, K., Mehta, A., Cichanowitz, N., Li, Q., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31279-5 · Cited by 569
Drug Design, Development and Therapy
(2020) · Drug Design Development and Therapy · doi:10.2147/dddt · Cited by 558
Thaçi, D., Blauvelt, A., Reich, K., Tsai, T.-F., Vanaclocha, F., Kingo, K., Ziv, M., Pinter, A., Hugot, S., You, R., et al. (2015) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2015.05.013 · Cited by 551
Menter, A., Feldman, S. R., Weinstein, G. D., Papp, K., Evans, R., Guzzo, C., Li, S., Dooley, L. T., Arnold, C., & Gottlieb, A. B. (2007) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2006.07.017 · Cited by 516
Gordon, K. B., Langley, R. G., Leonardi, C., Toth, D., Menter, M. A., Kang, S., Heffernan, M., Miller, B., Hamlin, R., Lim, L., et al. (2006) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2006.05.027 · Cited by 510
Paul, C., Cather, J., Gooderham, M., Poulin, Y., Mrowietz, U., Ferrandiz, C., Crowley, J., Hu, C., Stevens, R. M., Shah, K., et al. (2015) · British Journal of Dermatology · doi:10.1111/bjd.14164 · Cited by 484
Methotrexate versus Cyclosporine in Moderate-to-Severe Chronic Plaque Psoriasis
Heydendael, V. M. R., Spuls, P. I., Opmeer, B. C., de Borgie, C. A. J. M., Reitsma, J. B., Goldschmidt, W. F. M., Bossuyt, P. M. M., Bos, J. D., & de Rie, M. A. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021359 · Cited by 475
A Randomized Trial of Etanercept as Monotherapy for Psoriasis
Gottlieb, A. B. (2003) · Archives of Dermatology · doi:10.1001/archderm.139.12.1627 · Cited by 470
Papp, K. A., Reich, K., Paul, C., Blauvelt, A., Baran, W., Bolduc, C., Toth, D., Langley, R. G., Cather, J., Gottlieb, A. B., et al. (2016) · British Journal of Dermatology · doi:10.1111/bjd.14493 · Cited by 470
Self-citationDias, S., Sutton, A. J., Welton, N. J., & Ades, A. E. (2013) · Medical Decision Making · doi:10.1177/0272989x13485157 · Cited by 466
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Sbidian, E., Chaimani, A., Garcia-Doval, I., Do, G., Hua, C., Mazaud, C., Droitcourt, C., Hughes, C., Ingram, J. R., Naldi, L., et al. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011535.pub2 · Cited by 433
Reich, K., Armstrong, A. W., Langley, R. G., Flavin, S., Randazzo, B., Li, S., Hsu, M.-C., Branigan, P., & Blauvelt, A. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31773-8 · Cited by 381
Self-citationBlauvelt, A., Prinz, J. C., Gottlieb, A. B., Kingo, K., Sofen, H., Ruer-Mulard, M., Singh, V., Pathan, R., Papavassilis, C., Cooper, S., et al. (2015) · British Journal of Dermatology · doi:10.1111/bjd.13348 · Cited by 323
Reich, K., Gooderham, M., Thaçi, D., Crowley, J. J., Ryan, C., Krueger, J. G., Tsai, T.-F., Flack, M., Gu, Y., Williams, D. A., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30952-3 · Cited by 301
Self-citationAntipsoriatic effect of fumaric acid derivatives
Altmeyer, P. J., Mattlies, U., Pawlak, F., Hoffmann, K., Frosch, P. J., Ruppert, P., Wassilew, S. W., Horn, T., Kreysel, H. W., Lutz, G., et al. (1994) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(94)70121-0 · Cited by 300
Papp, K., Cather, J. C., Rosoph, L., Sofen, H., Langley, R. G., Matheson, R. T., Hu, C., & Day, R. M. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60642-4 · Cited by 282
Paul, C., Lacour, J. ‐., Tedremets, L., Kreutzer, K., Jazayeri, S., Adams, S., Guindon, C., You, R., Papavassilis, C., & the JUNCTURE study group (2015) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.12751 · Cited by 280
Papp, K., Thaçi, D., Reich, K., Riedl, E., Langley, R. G., Krueger, J. G., Gottlieb, A. B., Nakagawa, H., Bowman, E. P., Mehta, A., et al. (2015) · British Journal of Dermatology · doi:10.1111/bjd.13932 · Cited by 276
Old and New Biological Therapies for Psoriasis
Rønholt, K., & Iversen, L. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112297 · Cited by 240
Tsai, T.-F., Ho, J.-C., Song, M., Szapary, P., Guzzo, C., Shen, Y.-K., Li, S., Kim, K.-J., Kim, T.-Y., Choi, J.-H., et al. (2011) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2011.05.005 · Cited by 212
Barker, J., Hoffmann, M., Wozel, G., Ortonne, J.-P., Zheng, H., van Hoogstraten, H., & Reich, K. (2011) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2011.10615.x · Cited by 202
Reich, K., Gooderham, M., Green, L., Bewley, A., Zhang, Z., Khanskaya, I., Day, R. M., Goncalves, J., Shah, K., Piguet, V., et al. (2017) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14015 · Cited by 199
Reich, K., Pinter, A., Lacour, J. P., Ferrandiz, C., Micali, G., French, L. E., Lomaga, M., Dutronc, Y., Henneges, C., Wilhelm, S., et al. (2017) · British Journal of Dermatology · doi:10.1111/bjd.15666 · Cited by 192
ASAHINA, A., NAKAGAWA, H., ETOH, T., OHTSUKI, M., & THE ADALIMUMAB M04‐688 STUDY GROUP (2010) · The Journal of Dermatology · doi:10.1111/j.1346-8138.2009.00748.x · Cited by 184
Sawyer, L. M., Malottki, K., Sabry-Grant, C., Yasmeen, N., Wright, E., Sohrt, A., Borg, E., & Warren, R. B. (2019) · PLOS ONE · doi:10.1371/journal.pone.0220868 · Cited by 161
Flytström, I., Stenberg, B., Svensson, Å., & Bergbrant, I.-M. (2007) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2007.08284.x · Cited by 160
Reich, K., Ortonne, J.-P., Gottlieb, A. B., Terpstra, I. J., Coteur, G., Tasset, C., & Mease, P. (2012) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2012.10941.x · Cited by 158
Schmitt, J. M., Rosumeck, S., Thomaschewski, G., Sporbeck, B., Haufe, E., & Nast, A. (2013) · British Journal of Dermatology · doi:10.1111/bjd.12663 · Cited by 157
Gottlieb, A. B., Blauvelt, A., Thaçi, D., Leonardi, C. L., Poulin, Y. P., Drew, J., Peterson, L., Arendt, C. H., Burge, D. J., & Reich, K. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.04.012 · Cited by 157
Lecluse, L. L. A., Driessen, R. J. B., Spuls, P. I., de Jong, E. M. G. J., Stapel, S. O., van Doorn, M. B. A., Bos, J. D., & Wolbink, G. (2010) · Archives of Dermatology · doi:10.1001/archdermatol.2009.347 · Cited by 148
Nakagawa, H., Niiro, H., & Ootaki, K. (2015) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2015.10.009 · Cited by 147
Nast, A., Jacobs, A., Rosumeck, S., & Werner, R. N. (2015) · Journal of Investigative Dermatology · doi:10.1038/jid.2015.206 · Cited by 143
Gisondi, P., Giglio, M. D., Cotena, C., & Girolomoni, G. (2008) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2008.08564.x · Cited by 136
Lebwohl, M., Blauvelt, A., Paul, C. F., Sofen, H. L., Węgłowska, J., Piguet, V., Burge, D. J., Rolleri, R., Drew, J., Peterson, L., et al. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.04.013 · Cited by 134
Self-citationGelfand, J. M., Shin, D. B., Alavi, A. A., Torigian, D. A., Werner, T. J., Papadopoulos, M., Takeshita, J., Noe, M. H., Dey, A. K., Playford, M. P., et al. (2019) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2019.07.679 · Cited by 117
Ohtsuki, M., Kubo, H., Morishima, H., Goto, R., Zheng, R., & Nakagawa, H. (2018) · The Journal of Dermatology · doi:10.1111/1346-8138.14504 · Cited by 114
Sawyer, L., Cornic, L., Levin, L. Å., Gibbons, C. M., Møller, A. H., & Jemec, G. B. E. (2018) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.15277 · Cited by 106
Cai, L., Gu, J., Zheng, J., Zheng, M., Wang, G., Xi, L., Hao, F., Liu, X. ‐., Sun, Q. ‐., Wang, Y., et al. (2016) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.13746 · Cited by 102
Choosing First-Line Biologic Treatment for Moderate-to-Severe Psoriasis: What Does the Evidence Say?
Amin, M., No, D. J., Egeberg, A., & Wu, J. J. (2017) · American Journal of Clinical Dermatology · doi:10.1007/s40257-017-0328-3 · Cited by 83
An evolution in switching therapy for psoriasis patients who fail to meet treatment goals
Kerdel, F. A., & Zaiac, M. (2015) · Dermatologic Therapy · doi:10.1111/dth.12267 · Cited by 79
Bissonnette, R., Tardif, J., Harel, F., Pressacco, J., Bolduc, C., & Guertin, M. (2012) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.112.975730 · Cited by 76
Bagel, J., Nia, J. K., Hashim, P. W., Patekar, M., de Vera, A., Hugot, S., Sheng, K., Xia, S., Gilloteau, I., Muscianisi, E., et al. (2018) · Dermatology and Therapy · doi:10.1007/s13555-018-0265-y · Cited by 75
Evaluation and Management of Psoriasis: An Internist's Guide
Levine, D. E., & Gottlieb, A. B. (2009) · Medical Clinics of North America · doi:10.1016/j.mcna.2009.08.003 · Cited by 72
Signorovitch, J., Betts, K. A., Yan, Y. S., LeReun, C., Sundaram, M., Wu, E. Q., & Mulani, P. M. (2014) · British Journal of Dermatology · doi:10.1111/bjd.13437 · Cited by 69
Self-citationOhtsuki, M., Okubo, Y., Komine, M., Imafuku, S., Day, R. M., Peng, C., Petric, R., Maroli, A. N., & Nemoto, O. (2017) · The Journal of Dermatology · doi:10.1111/1346-8138.13829 · Cited by 69
Blauvelt, A., Ferris, L. K., Yamauchi, P. S., Qureshi, A. A., Leonardi, C., Farahi, K., Fakharzadeh, S. S., Hsu, M.-C., Li, S., Chevrier, M. R., et al. (2017) · British Journal of Dermatology · doi:10.1111/bjd.15722 · Cited by 66
Cui, L., Chen, R., Subedi, S., Yu, Q., Gong, Y., Chen, Z., & Shi, Y. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.06.020 · Cited by 66
Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis
Haugh, I. M., Preston, A., Kivelevitch, D. N., & Menter, A. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s167149 · Cited by 66
Sawyer, L., Fotheringham, I., Wright, E., Yasmeen, N., Gibbons, C., & Moeller, A. H. (2018) · Journal of Dermatological Treatment · doi:10.1080/09546634.2018.1427205 · Cited by 44
Xu, G., Xia, M., Jiang, C., Yu, Y., Wang, G., Yuan, J., & Duan, X. (2018) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2018.12.006 · Cited by 32
Armstrong, A. W., Betts, K. A., Signorovitch, J., Sundaram, M., Li, J., Ganguli, A. X., & Wu, E. Q. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2018.1457516 · Cited by 29
Self-citationWan, M. T., Alvarez, J. L. R., Shin, D. B., Dommasch, E. D., Wu, J. J., & Gelfand, J. M. (2018) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.15174 · Cited by 12
Risankizumab in Moderate-to-Severe Plaque Psoriasis
Serrano, L., Maloney, V., & Gordon, K. B. (2019) · Immunotherapy · doi:10.2217/imt-2019-0116 · Cited by 7
Cited by
Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review
Armstrong, A. W., & Read, C. (2020) · JAMA · doi:10.1001/jama.2020.4006 · Cited by 2,335
Self-citationTherapeutics targeting the IL-23 and IL-17 pathway in psoriasis
Ghoreschi, K., Balato, A., Enerbäck, C., & Sabat, R. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00184-7 · Cited by 668
Challenges and Future Trends in the Treatment of Psoriasis
Lee, H.-J., & Kim, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713313 · Cited by 315
Metadata
- Authors
- Armstrong, A. W., Puig, L., Joshi, A., Skup, M., Williams, D., Li, J., Betts, K. A., & Augustin, M.
- Venue
- JAMA Dermatology
- Publisher
- American Medical Association (AMA)
- Published
- 2020-03-01
- Volume
- 156
- Issue
- 3
- Pages
- 258
- ISSN
- 2168-6068 (ISSN-L)
- OpenAlex
- W3005392748
- Cited by
- 294
- References
- 78
- FWCI
- 11.27
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.